Anders Ullén
About
Anders Ullén is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, Anders Ullén has authored 88 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Surgery, 33 papers in Pulmonary and Respiratory Medicine and 30 papers in Oncology. Recurrent topics in Anders Ullén's work include Bladder and Urothelial Cancer Treatments (45 papers), Urinary and Genital Oncology Studies (32 papers) and Prostate Cancer Treatment and Research (19 papers). Anders Ullén is often cited by papers focused on Bladder and Urothelial Cancer Treatments (45 papers), Urinary and Genital Oncology Studies (32 papers) and Prostate Cancer Treatment and Research (19 papers). Anders Ullén collaborates with scholars based in Sweden, United Kingdom and United States. Anders Ullén's co-authors include Sten Nilsson, Amir Sherif, Per‐Uno Malmström, Robert Rosenblatt, Rolf Wahlqvist, Erkki Rintala, Theocharis Panaretakis, Lena Lennartsson, Jeffrey Yachnin and Ulrika Harmenberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Anders Ullén
80 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anders Ullén Sweden | 18 | 646 | 449 | 398 | 386 | 195 | 88 | 1.3k | ||
| Tony Elliott United Kingdom | 22 | 535 0.8× | 503 1.1× | 326 0.8× | 736 1.9× | 213 1.1× | 58 | 1.6k | ||
| Malcolm Crundwell United Kingdom | 15 | 875 1.4× | 328 0.7× | 521 1.3× | 514 1.3× | 245 1.3× | 28 | 1.6k | ||
| Matt D. Galsky United States | 21 | 1.0k 1.6× | 982 2.2× | 445 1.1× | 407 1.1× | 174 0.9× | 198 | 1.8k | ||
| Álvaro S. Sarkis Brazil | 14 | 483 0.7× | 377 0.8× | 559 1.4× | 439 1.1× | 171 0.9× | 34 | 1.3k | ||
| Nabil Adra United States | 19 | 757 1.2× | 460 1.0× | 313 0.8× | 622 1.6× | 146 0.7× | 119 | 1.4k | ||
| Takeshi Ujike Japan | 19 | 285 0.4× | 270 0.6× | 454 1.1× | 437 1.1× | 313 1.6× | 74 | 1.1k | ||
| Javier Puente Spain | 18 | 320 0.5× | 786 1.8× | 424 1.1× | 639 1.7× | 426 2.2× | 164 | 1.5k | ||
| Arash Rezazadeh Kalebasty United States | 14 | 442 0.7× | 630 1.4× | 364 0.9× | 531 1.4× | 164 0.8× | 69 | 1.2k | ||
| Mototsugu Muramaki Japan | 22 | 429 0.7× | 424 0.9× | 625 1.6× | 582 1.5× | 235 1.2× | 90 | 1.4k | ||
| Antony C. P. Riddick United Kingdom | 22 | 227 0.4× | 259 0.6× | 522 1.3× | 475 1.2× | 351 1.8× | 46 | 1.1k |
Countries citing papers authored by Anders Ullén
Since
Specialization
Citations
This map shows the geographic impact of Anders Ullén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Ullén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Ullén more than expected).
Fields of papers citing papers by Anders Ullén
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anders Ullén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Ullén. The network helps show where Anders Ullén may publish in the future.
Co-authorship network of co-authors of Anders Ullén
This figure shows the co-authorship network connecting the top 25 collaborators of Anders Ullén. A scholar is included among the top collaborators of Anders Ullén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Ullén. Anders Ullén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Svedman, Fernanda Costa, et al.. (2025). Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab. Urologic Oncology Seminars and Original Investigations. 43(8). 467.e21–467.e29.
2.
Ullén, Anders, Firas Aljabery, Truls Gårdmark, et al.. (2025). Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease. Scandinavian Journal of Urology. 60. 76–82.
3.
Liedberg, Fredrik, Truls Gårdmark, Oskar Hagberg, et al.. (2024). Treatment Related to Urinary Tract Infections Is Associated with Delayed Diagnosis of Urinary Bladder Cancer: A Nationwide Population-based Study. European Urology Oncology. 8(1). 119–125.
4.
Liedberg, Fredrik, Oskar Hagberg, Firas Aljabery, et al.. (2024). Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey. Scandinavian Journal of Urology. 59. 19–25.
5.
Bellmunt, Joaquim, Thomas Powles, Se Hoon Park, et al.. (2024). Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.. Journal of Clinical Oncology. 42(16_suppl). 4566–4566.
6.
Powles, Thomas, Se Hoon Park, Claudia Caserta, et al.. (2023). Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of Clinical Oncology. 41(19). 3486–3492.
7.
Bergengren, Oskar, Anna Bill‐Axelson, Hans Garmo, et al.. (2023). Short term outcomes after robot assisted and open cystectomy - A nation-wide population-based study. European Journal of Surgical Oncology. 49(4). 868–874.
8.
Sjödahl, Gottfrid, Pontus Eriksson, Mattias Höglund, et al.. (2023). Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer. International Journal of Cancer. 154(1). 180–190.
9.
Fonseca, Pedro, Sue‐Hwa Lin, Christopher J. Logothetis, et al.. (2023). Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration‐resistant prostate cancer. The Prostate. 83(10). 950–961.
10.
Viktorsson, Kristina, Petra Hååg, Bo Franzén, et al.. (2022). Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome. Molecular Oncology. 16(20). 3620–3641.
11.
Häggström, Christel, Oskar Hagberg, Truls Gårdmark, et al.. (2022). Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. BMJ Open. 12(12). e064898–e064898.
12.
Jahnson, Staffan, Truls Gårdmark, Abolfazl Hosseini, et al.. (2021). Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study. Bladder Cancer. 7(2). 161–171.
13.
Als, Anne Birgitte, Mads Agerbæk, Henriette Lindberg, et al.. (2021). Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen. Bladder Cancer. 8(1). 71–80.
14.
Sjödahl, Gottfrid, Carina Bernardo, Gunilla Chebil, et al.. (2021). Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. European Urology. 81(5). 523–532.
15.
Crippa, Alessio, Bram De Laere, Andrea Discacciati, et al.. (2020). The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 21(1). 579–579.
16.
Chen, Ruoqing, Fredrik Liedberg, Ove Andrén, et al.. (2019). No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World Journal of Urology. 38(2). 381–388.
17.
Jensen, Niels Viggo, et al.. (2016). Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis. Oncology Letters. 12(2). 1293–1300.
18.
Viktorsson, Kristina, Lena Kanter, Amir Sherif, et al.. (2014). Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 32(8). 1215–1224.
19.
Edgren, M, Per Albertsson, Linda Lundberg, et al.. (2006). High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique: Technical and methodological aspects. International Journal of Oncology. 29(6). 1517–24.
20.
Ullén, Anders, et al.. (1995). In vivo and in vitro interactions between idiotypic and antiidiotypic monoclonal antibodies against placental alkaline phosphatase. Journal of Immunological Methods. 183(1). 155–165.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tony Elliott Breakdown of academic impact, for papers by Malcolm Crundwell Breakdown of academic impact, for papers by Matt D. Galsky Breakdown of academic impact, for papers by Álvaro S. Sarkis Breakdown of academic impact, for papers by Nabil Adra Breakdown of academic impact, for papers by Takeshi Ujike Breakdown of academic impact, for papers by Javier Puente Breakdown of academic impact, for papers by Arash Rezazadeh Kalebasty Breakdown of academic impact, for papers by Mototsugu Muramaki Breakdown of academic impact, for papers by Antony C. P. Riddick